• +1-646-491-9876
    • +91-20-67278686

    Search

    Cough - Pipeline Review, H1 2017

    Cough - Pipeline Review, H1 2017

    • Report Code ID: RW0001709428
    • Category Pharmaceuticals
    • No. of Pages 74
    • Publication Month Mar-17
    • Publisher Name Global Markets Direct
    Cough - Pipeline Review, H1 2017

    Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Cough - Pipeline Review, H1 2017, provides an overview of the Cough (Respiratory) pipeline landscape.

    Cough is a common reflex action that aims to clear the throat of mucus or foreign irritants. Dry cough, chronic cough and whooping cough (also known as pertussis) are distinct types of cough. Symptoms include runny or stuffy nose, hoarseness, wheezing and shortness of breath, heartburn or a sour taste in mouth and rarely coughing up blood. The predisposing factors include asthma, chronic obstructive pulmonary disease, cigarette smoking, lung diseases such as bronchiectasis, interstitial lung disease, or tumors, lung infections such as pneumonia or acute bronchitis and allergic rhino sinusitis. Treatment includes cough suppressants, oral expectorants, and topical (externally applied) drugs.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Cough - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Cough (Respiratory) , complete with analysis by stage of development, drug target, mechanism of action (MoA) , route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Cough (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Cough and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Preclinical, Discovery and Unknown stages are 2, 1, 6, 9, 2 and 4 respectively.

    Cough (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Cough (Respiratory) .
    - The pipeline guide reviews pipeline therapeutics for Cough (Respiratory) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Cough (Respiratory) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Cough (Respiratory) therapeutics based on mechanism of action (MoA) , drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Cough (Respiratory)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Cough (Respiratory) .
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Cough (Respiratory) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Cough - Overview
    Cough - Therapeutics Development
    Pipeline Overview
    Pipeline by Companies
    Products under Development by Companies
    Cough - Therapeutics Assessment
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Cough - Companies Involved in Therapeutics Development
    Afferent Pharmaceuticals Inc
    Alitair Pharmaceuticals Inc
    Alveonix AG
    AstraZeneca Plc
    BELLUS Health Inc
    Charleston Laboratories Inc
    Conrig Pharma ApS
    Daewoong Pharmaceutical Co Ltd
    Hyundai Pharmaceutical Co Ltd
    NeRRe Therapeutics Ltd
    Orbis Biosciences Inc
    Patara Pharma Inc
    PhytoHealth Corp
    Pila Pharma AB
    Vernalis Plc
    Cough - Drug Profiles
    AF-219 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Ax-8 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    benzonatate - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    BLU-5937 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    CCP-05 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    CCP-06 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    CCP-07 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    CCP-08 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    CLAT-313 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    codeine + guaifenesin - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    cromolyn sodium - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    DWJ-1340 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    guaifenesin + hydrocodone - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    guaifenesin ER - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    lesogaberan - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    levodropropizine CR - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ORB-110 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    orvepitant maleate - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    PHCA-01 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    S-1226 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ST-015 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ST-016 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ST-018 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    XEND-0501 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Cough - Dormant Projects
    Cough - Discontinued Products
    Cough - Product Development Milestones
    Featured News & Press Releases
    Dec 21, 2016: FDA accepts CCP-08 NDA for full review
    Sep 07, 2016: Patara Pharma Announces Positive Phase 2 Results for the Treatment of Refractory Chronic Cough in Patients with Idiopathic Pulmonary Fibrosis
    Sep 06, 2016: Vernalis annopunces that FDA accepts CCP-07 NDA for full review
    Jul 08, 2016: Vernalis Announces Successful Completion of CCP-08 Pivotal Multiple-Dose Comparative Bioavailability Study
    May 16, 2016: Afferent Pharmaceuticals Presents Updated Positive Results with AF-219 from Phase 2B Chronic Cough Study at the 2016 American Thoracic Society International Conference
    May 03, 2016: Patara Pharma Appoints Biotechnology Industry Leader John Schmid to Board of Directors
    Apr 25, 2016: Afferent Pharmaceuticals Announces Presentation of Chronic Cough Clinical Data at the Upcoming American Thoracic Society 2016 International Conference
    Apr 14, 2016: Vernalis Announces Successful Completion of CCP-07 Pivotal Multiple-Dose Comparative Bioavailability Study
    Apr 13, 2016: Vernalis Announces Successful Completion of CCP-08 Pivotal Single-Dose Comparative Bioavailability Study
    Dec 21, 2015: Vernalis Announces Successful Completion of CCP-07 Pivotal Single-Dose Comparative Bioavailability Study
    Oct 12, 2015: Vernalis announces start of CCP-08 12 month stability testing
    Sep 28, 2015: Afferent Pharmaceuticals Announces Positive Results in Phase 2b Chronic Cough Trial
    Jul 01, 2015: Spriaso Announces Approval of New Drug Application for the Long Acting Codeine Antitussive With a Popular Anti-Histamine
    Jun 11, 2015: Vernalis announces CCP-07 starts 12 month stability testing
    Nov 25, 2014: Afferent Clinical Data Demonstrating AF-219 Treatment Reduces Cough Frequency by 75% in Chronic Cough Is Published In The Lancet
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development for Cough, H1 2017
    Number of Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017 (Contd..1) , H1 2017
    Number of Products by Stage and Target, H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Cough - Pipeline by Afferent Pharmaceuticals Inc, H1 2017
    Cough - Pipeline by Alitair Pharmaceuticals Inc, H1 2017
    Cough - Pipeline by Alveonix AG, H1 2017
    Cough - Pipeline by AstraZeneca Plc, H1 2017
    Cough - Pipeline by BELLUS Health Inc, H1 2017
    Cough - Pipeline by Charleston Laboratories Inc, H1 2017
    Cough - Pipeline by Conrig Pharma ApS, H1 2017
    Cough - Pipeline by Daewoong Pharmaceutical Co Ltd, H1 2017
    Cough - Pipeline by Hyundai Pharmaceutical Co Ltd, H1 2017
    Cough - Pipeline by NeRRe Therapeutics Ltd, H1 2017
    Cough - Pipeline by Orbis Biosciences Inc, H1 2017
    Cough - Pipeline by Patara Pharma Inc, H1 2017
    Cough - Pipeline by PhytoHealth Corp, H1 2017
    Cough - Pipeline by Pila Pharma AB, H1 2017
    Cough - Pipeline by Vernalis Plc, H1 2017
    Cough - Dormant Projects, H1 2017
    Cough - Dormant Projects, H1 2017 (Contd..1) , H1 2017
    Cough - Discontinued Products, H1 2017

    List of Figures

    Number of Products under Development for Cough, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products by Targets, H1 2017
    Number of Products by Stage and Targets, H1 2017
    Number of Products by Mechanism of Actions, H1 2017
    Number of Products by Stage and Mechanism of Actions, H1 2017
    Number of Products by Routes of Administration, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Stage and Molecule Types, H1 2017
    Afferent Pharmaceuticals Inc
    Alitair Pharmaceuticals Inc
    Alveonix AG
    AstraZeneca Plc
    BELLUS Health Inc
    Charleston Laboratories Inc
    Conrig Pharma ApS
    Daewoong Pharmaceutical Co Ltd
    Hyundai Pharmaceutical Co Ltd
    NeRRe Therapeutics Ltd
    Orbis Biosciences Inc
    Patara Pharma Inc
    PhytoHealth Corp
    Pila Pharma AB
    Vernalis Plc

    Request for Sample

    Report Url http://www.reportsweb.com//cough-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//cough-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//cough-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments